Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models

Morimoto,Megumi; Aikawa,Katsuji; Hara,Takahito; Yamaoka,Masuo

doi:10.3892/ol.2017.7200

Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models

Authors:
- Megumi Morimoto
- Katsuji Aikawa
- Takahito Hara
- Masuo Yamaoka
View Affiliations

Affiliations: Oncology Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251‑8555, Japan, Integrated Technology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251‑8555, Japan
Published online on: October 17, 2017 https://doi.org/10.3892/ol.2017.7200
Pages: 8066-8071

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer cachexia is a syndrome that impairs the quality of life and overall survival of patients, and thus the effectiveness of anticancer agents. There are no effective therapies for cancer cachexia due to the complexity of the syndrome, and insufficient knowledge of its pathogenesis results in difficulty establishing appropriate animal models. Previously, promising results have been obtained in clinical trials using novel agents including the ghrelin receptor agonist anamorelin, and the selective androgen receptor modulator (SARM) enobosarm to treat cachexia in patients with cancer. The present study examined the pharmacological effects of SARM‑2f, a novel non‑steroidal small molecule SARM, in animal models. SARM‑2f increased body and skeletal muscle weight without significantly increasing the weight of the seminal vesicles or prostates of the castrated male rats. In the mice with tumor necrosis factor α‑induced cachexia, SARM‑2f and TP restored body weight, carcass weight, and food consumption rate. In the C26 and G361 cancer cachexia animal models, body and carcass weight, lean body mass, and the weight of the levator ani muscle were increased by SARM‑2f and TP treatments. Tissue selectivity of SARM‑2f was also observed in these animal models. The results demonstrate the anabolic effects of SARM‑2f in a cytokine‑induced cachexia model and other cancer cachexia models, and suggest that SARM‑2f may be a novel therapeutic option for cachexia in patients with cancer.

View Figures

View References

1	Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI
2	Argilés JM, Busquets S, Stemmler B and López-Soriano FJ: Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
3	Fearon KC, Glass DJ and Guttridge DC: Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab. 16:153–166. 2012. View Article : Google Scholar : PubMed/NCBI
4	Cooper C, Burden ST, Cheng H and Molassiotis A: Understanding and managing cancer-related weight loss and anorexia: Insights from a systematic review of qualitative research. J Cachexia Sarcopenia Muscle. 6:99–111. 2015. View Article : Google Scholar : PubMed/NCBI
5	Tuca A, Jimenez-Fonseca P and Gascón P: Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 88:625–636. 2013. View Article : Google Scholar : PubMed/NCBI
6	Porporato PE: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5:e2002016. View Article : Google Scholar : PubMed/NCBI
7	Coss CC, Bohl CE and Dalton JT: Cancer cachexia therapy: A key weapon in the fight against cancer. Curr Opin Clin Nutr Metab Care. 14:268–273. 2011. View Article : Google Scholar : PubMed/NCBI
8	Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT and Steiner MS: Muscle wasting in cancer cachexia: Clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 62:265–279. 2011. View Article : Google Scholar : PubMed/NCBI
9	Madeddu C, Mantovani G, Gramignano G and Macciò A: Advances in pharmacologic strategies for cancer cachexia. Expert Opin Pharmacother. 16:2163–2177. 2015. View Article : Google Scholar : PubMed/NCBI
10	Molfino A, Amabile MI, Fanelli Rossi F and Muscaritoli M: Novel therapeutic options for cachexia and sarcopenia. Expert Opin Biol Ther. 16:1239–1244. 2016. View Article : Google Scholar : PubMed/NCBI
11	Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, DeGracia B, Willey JS and Bruera E: The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: A pilot study. Cancer. 107:2949–2957. 2006. View Article : Google Scholar : PubMed/NCBI
12	Burney BO, Hayes TG, Smiechowska J, Cardwell G, Papusha V, Bhargava P, Konda B, Auchus RJ and Garcia JM: Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab. 97:E700–E709. 2012. View Article : Google Scholar : PubMed/NCBI
13	Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, et al: Adverse events associated with testosterone administration. N Engl J Med. 363:109–122. 2010. View Article : Google Scholar : PubMed/NCBI
14	Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, et al: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 10:1829–1836. 2013. View Article : Google Scholar
15	Aikawa K, Miyawaki T, Hitaka T, Imai YN, Hara T, Miyazaki J, Yamaoka M, Kusaka M, Kanzaki N, Tasaka A, et al: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I. Bioorg Med Chem. 23:2568–2578. 2015. View Article : Google Scholar : PubMed/NCBI
16	Dwarkasing JT, Boekschoten MV, Argilès JM, van Dijk M, Busquets S, Penna F, Toledo M, Laviano A, Witkamp RF and van Norren K: Differences in food intake of tumor-bearing cachectic mice are associated with hypothalamic serotonin signaling. J Cachexia Sarcopenia Muscle. 6:84–94. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ballarò R, Costelli P and Penna F: Animal models for cancer cachexia. Curr Opin Support Palliat Care. 10:281–287. 2016. View Article : Google Scholar : PubMed/NCBI
18	Talbert EE, Metzger GA, He WA and Guttridge DC: Modeling human cancer cachexia in colon 26 tumor-bearing adult mice. J Cachexia Sarcopenia Muscle. 5:321–328. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ustünel I, Akkoyunlu G and Demir R: The effect of testosterone on gastrocnemius muscle fibres in growing and adult male and female rats: A histochemical, morphometric and ultrastructural study. Anat Histol Embryol. 32:70–79. 2003. View Article : Google Scholar : PubMed/NCBI
20	Urban RJ: Growth hormone and testosterone: Anabolic effects on muscle. Horm Res Paediatr. 76 Suppl 1:S81–S83. 2011. View Article : Google Scholar
21	De Gendt K and Verhoeven G: Tissue- and cell-specific functions of the androgen receptor revealed through conditional knockout models in mice. Mol Cell Endocrinol. 352:13–25. 2012. View Article : Google Scholar : PubMed/NCBI
22	Aikawa K, Asano M, Ono K, Habuka N, Yano J, Wilson K, Fujita H, Kandori H, Hara T, Morimoto M, et al: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate. Bioorg Med Che. 25:3330–3349.. 2017. View Article : Google Scholar
23	Argiles JM, Lopez-Soriano FJ and Busquets S: Counteracting inflammation: A promising therapy in cachexia. Crit Rev Oncog. 17:253–262. 2012. View Article : Google Scholar : PubMed/NCBI
24	Thompson RW, McClung JM, Baltgalvis KA, Davis JM and Carson JA: Modulation of overload-induced inflammation by aging and anabolic steroid administration. Exp Gerontol. 41:1136–1148. 2006. View Article : Google Scholar : PubMed/NCBI
25	Srinath R and Dobs A: Enobosarm (GTx-024, S-22): A potential treatment for cachexia. Future Oncol. 10:187–194. 2014. View Article : Google Scholar : PubMed/NCBI
26	Dillon EL, Basra G, Horstman AM, Casperson SL, Randolph KM, Durham WJ, Urban RJ, Diaz-Arrastia C, Levine L, Hatch SS, et al: Cancer cachexia and anabolic interventions: A case report. J Cachexia Sarcopenia Muscle. 3:253–263. 2012. View Article : Google Scholar : PubMed/NCBI
27	Del Fabbro E, Garcia JM, Dev R, Hui D, Williams J, Engineer D, Palmer JL, Schover L and Bruera E: Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: A preliminary double-blind placebo-controlled trial. Support Care Cancer. 21:2599–2607. 2013. View Article : Google Scholar : PubMed/NCBI
28	de Vooqt HJ, Smith PH, Pavone-Macaluso M, de Pauw M and Suciu S: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762. J Urol. 135:303–307. 1986. View Article : Google Scholar : PubMed/NCBI
29	Ponnusamy S, Sullivan RD, Thiyagarajan T, Tillmann H, Getzenberg RH and Narayanan R: Tissue selective androgen receptor modulators (SARMs) increase pelvic floor muscle mass in ovariectomized mice. J Cell Biochem. 118:640–646. 2017. View Article : Google Scholar : PubMed/NCBI
30	Chisamore MJ, Gentile MA, Dillon GM, Baran M, Gambone C, Riley S, Schmidt A, Flores O, Wilkinson H and Alves SE: A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice. J Steroid Biochem Mol Biol. 163:88–97. 2016. View Article : Google Scholar : PubMed/NCBI
31	Blanqué R, Lepescheux L, Auberval M, Minet D, Merciris D, Cottereaux C, Clément-Lacroix P, Delerive P and Namour F: Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization. BMC Musculoslelet Disord. 15:2912014. View Article : Google Scholar
32	Akita K, Harada K, Ichihara J, Takata N, Takahashi Y and Saito K: A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate. Eur J Pharmacol. 720:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
33	Zhang X, Allan GF, Tannenbaum P, Sbriscia T, Linton O, Lai MT, Haynes-Johnson D, Bhattacharjee S, Lundeen SG and Sui Z: Pharmacological characterization of an imidazolopyrazole as novel selective androgen receptor modulator. J Steroid Biochem Mol Biol. 134:51–58. 2013. View Article : Google Scholar : PubMed/NCBI
34	Narayanan R, Mohler ML, Bohl CE, Miller DD and Dalton JT: Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 6:e0102008.PubMed/NCBI
35	Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD and Dalton JT: Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol. 22:2448–2465. 2008. View Article : Google Scholar : PubMed/NCBI
36	Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML and Dalton JT: Study design and rationale for phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials). Curr Oncol Rep. 18:372016. View Article : Google Scholar : PubMed/NCBI
37	Garber K: No longer going to waste. Nat Biotechnol. 34:458–461. 2016. View Article : Google Scholar : PubMed/NCBI